Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Overdue PR on JVs
i would be
This stock was immensely shorted and this pr might have triggered a "short" squeeze. hold on to your hats this could be "big_green" as the shorts hurry to cover at a loss.
A lot of eyes waiting for this stock to start running again. Many longs holding the price like responsible investors. The news should shake things up quite a bit. beep... beep... welcome to the loading zone.
Worried about funding???
Read up...
>>>>http://ih.advfn.com/p.php?pid=nmona&article=49528162<<<<
This is from 2011 and AMBS is still receiving tranches of up to 750,000 as they complete milestones for 36 months. Subject to terms and conditions. Along with revolutionary concepts and quality management AMBS has a massive upside. IMHO
You might see people starting to move in on cheap shares because of heavy speculation of a 510k cleared device release. and when they announced today that they are coming out with a company overview that will mostly likely out line a release date.
I have a few friends who like to know about good investments and we might just see a nice bounce when this thing hits the right entry point/ or conformation.
I agree it worries me more when things don't consolidate, now we will have supports and the stock as whole will be stronger and be able to make the next strong leg.
Epgl is in a re-trace, nothing goes straight up and traders are smart to take profits and gamble with free shares. The company twitter account lets us know that this is purely profit takers and everything is on track and the outlook is very positive. If anyone would like to see the google doc i have been putting tigether for a few weeks now to gather information on EPGl just pm me. EPGL Long.
http://www.epglmed.com/EPGL_Medical_Sciences/Home.html
Google Doc has been updated! Check it out:
https://docs.google.com/document/d/1V10erwVdBvy6Um35Ay8XV0wV3TAPr6oME2fJG_jFvl4/edit
5/31 Update:
Happy New Years to all. 2012 has been a wild ride, but the best is still to come. AMBS is announcing their data results January 8th, with Dr. Rubinfield presenting right after on the commercialization potential of MANF. Here’s forbes’ profile on Rubinfield, his worth, and his accomplishments:
http://www.forbes.com/profile/joseph-rubinfeld/
As you can see, Rubinfield is essentially the Steve Jobs of biotechs. To have him presenting for our penny stock speaks volume. These conferences are where biotechs customarily release their data results, and it is truly an exciting time given the nature of our preliminary results (30-40% better than GDNF). GDNF was valued at $250 million in this stage of its development, which is around 1/10th of our market value at almost any given day! But this is all old news, I now would like to put an end to the dilution conspiracy theory which has been overtaking certain boards.
On December 3rd, 2012, Amarantus Biosciences issued the following PR explaining the CUSIP change and addressed dilution: http://ih.advfn.com/p.php?pid=nmona&article=55291531
“The Company believes that its fundamentals remain strong and is looking forward to continuing to update the marketplace regarding developments on an ongoing basis. The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals.”
Interpreting a PR doesn’t get much easier than this. Publicly traded companies cannot lie through their SEC filings and PRs or they may face serious repercussions. With the huge potential AMBS has infront of it, logical rhetoric and a few deep breaths should ease any fears of shareholders who are unsure about dilution. Furthermore, if the company was to sell any shares in the market we would be the first to know about it via an 8k, form 3.02. This is a mandatory step for any company that wishes to sell even a small amount of shares. Read about it for yourself here: http://www.sec.gov/about/forms/form8-k.pdf and control+f or command+f “3.02” to find the section on the filing I referred to.
The outcries for dilution, IMO, have not been warranted whatsoever. Some have claimed that the .1 promissory notes some of us longs remember from a month ago are about to be sold off so the high net investors can break even. This is just plain wrong, and makes me question the motives of those trying to claim this. When AMBS secured its 1.1 million in private financing (view here http://finance.yahoo.com/news/amarantus-biosciences-secures-1-1-195300631.html ).
The filing clearly states that: can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time.”"> can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time.”" />
Doing your proper DD will prevent yourself from being scammed out of selling your shares for less than they are worth, or buying shares that are overvalued. Do not trust what others say, you must check every fact and pull them straight from SEC filings, not message boards. I hope all investors take the time to read the 10qs, and 8ks for not only AMBS, but all their future investments as well. This google doc will get you started nicely, but still only scrapes the surface of outlining AMBS’ true potential. Check every fact in this as well, for I am a human just like you and am subject to certain biases and misinterpretations.
As always, I continue to hold long and have not sold any of my shares. I think the true value of AMBS will be much clearer when we gap up January 9th. Hope to see all my fellow longs there with me when it goes down. I stand by my price target range of $2+, and will continue to hold all my shares until it gets there or the information we have at our hands changes. I am a young investor and have the opportunity to invest aggressively, so remember to only invest what you are comfortable losing. Although that seems like a long shot here, you never knows.
Happy to New Years to all, look forward to a strong 2013!
Can anyone post this 1.40 pps in a screen shot. thank you
This is what this board should be about, a collaboration of information. Not bears and bulls slinging mud at each other. I think we can all learn from this proper post.
i would like to see evidence of this so called pumping and dumping.
MJfox goes on about BIOMARKERS...Look what we acquired today
12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases
http://www.katiecouric.com/on-the-show/2012/12/26/michael-j-fox-dec-26-2012/
This is game changing. The day MJF goes on a mass media outlet and refers directly to a test for Parkinson's , AMBS secures the pattens for such a test. Connect the dots people. 50 and 200 day crossover, rubinfield not only showing up in person to the ambs presentation of data but then giving his own presentation on the profitability of ambs products. Room to run , open pastures. 100 and 200 ma crossover on the horizon.
Things to come.
The 8th, what a day that will be
The MJF full backing press release, what a day
and then primate testing and serious money.
And by the way all this might become even more exponential if ambs follows through and files for anorphan drug.
imo,
fmarca1
If your a long you will want to click this link.
MJF on the campaign trail for ambs.
*******************
http://www.katiecouric.com/on-the-show/2012/12/26/michael-j-fox-dec-26-2012/
*******************
Ambs long and have been
But he that dares not grasp the thorn should never crave the rose. Ambs long
Patience. So much speculation, so many expectations. This stock moves quickly but it seems here on IHUB that AMBS can't move fast enough to compensate for so many weak hands and so many people seeking instant gratification. People need to stop playing with their mortgage payments. imho